Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

OTC drugmakers face an uphill battle on Amazon. But they should still be there, expert says.....           Pfizer, plotting 41 price hikes for January, returns to 'business as normal' after price-raising pause.....           Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst.....           Pfizer, Merck KGaA's Bavencio flunks another trial, this time in ovarian cancer.....           Seattle Genetics' Adcetris scores quick lymphoma OK under FDA's new review program.....           Tesaro, hit hard by recent trial woes, hunts buyers?again: report.....           Seqirus to spend $140M, add 120 jobs at U.S. plant as it takes cell-based flu vaccines global.....           Allergan taps 'Sex and the City' actress to talk 'denim denial' for CoolSculpting.....           FiercePharmaAsia?Samsung BioLogics' crisis; Merck's Gardasil supply; China?s vaccine solution.....           After historic win, Lilly partner Chi-Med?s Elunate flops in lung cancer.....           Takeda investors mount last-minute effort to stymie Shire deal: FT.....           AstraZeneca's Imfinzi fails key Mystic trial in lung cancer. What now?.....           Eli Lilly weighs $200M-plus sale of declining China drug portfolio: report.....           Bristol-Myers Squibb laying off 69 employees in Florida in push to 'focus resources'.....           Johnson & Johnson scores back-to-back victories in talc mesothelioma cases.....           Repeat violations stack up at Dr. Reddy's cancer drug plant.....           Novartis plans more ?autonomy? for Sandoz. But don't confuse that with a spinoff: report.....           Lilly's third-to-market Emgality nets FDA 'breakthrough' in cluster headache.....           AbbVie's Orilissa makes its uterine fibroids case with double phase 3 win.....           GSK seeks paediatric indication for Nucala in severe eosinophilic asthma.....           Pfizer and Merck?s avelumab fails to improve OS or PFS in Javelin ovarian cancer trial.....           Aries Pharmaceuticals gets FDA nod for Aemcolo to treat Travelers? Diarrhea.....           Merck starts rolling FDA submission for its Ebola vaccine, aiming to finish next year.....           Mitsubishi Tanabe spotlights overlooked teen ALS caregivers with artistic effort.....           Seniors want drug prices in ads. Young people? Eh, whatever: survey.....           Merck's Keytruda picks up first-in-class survival win in esophageal cancer.....           Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects.....           Pfizer falls short in U.K. patent appeal for blockbuster Lyrica.....           Samsung BioLogics stock listing, CEO in jeopardy over accounting fraud.....           Pfizer rolls out Retacrit, a biosim to Amgen and J&J anemia blockbusters, at a big discount.....           Johnson & Johnson backs new Invokana CV nod with series of awareness tweets.....           Express Scripts ramps up list-price pressure with newfangled 'Flex' formulary.....           Roche's Tecentriq blazes toward first-in-class breast cancer nod with FDA 'priority' tag.....           AstraZeneca offloads RSV drug to Sobi for $1.5B, its largest divestiture in 5 years.....           AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries.....           AstraZeneca?s Imfinzi fails to improve OS in Mystic lung cancer trial.....           FDA approves Novartis drug Promacta for first-line SAA.....           Boehringer, Epizyme announce $300m oncology therapy program.....           BMS secures positive CHMP opinion for Opdivo- Yervoy combo in RCC.....           Nexus Pharmaceuticals gets FDA nod for Arsenic Trioxide injection in 10mg per 10mL vial.....           BioMarin-sponsored hemophilia musical debuts with teen singers, writers and actors.....           Machine learning for pharma marketers: The time is now to budget, experiment and adjust, expert says.....           Sandoz recalls losartan products that contain impurity.....           U.K. MPs threaten to release pricing info if Vertex, NHS don't strike Orkambi deal.....           AstraZeneca, Merck's Lynparza scores speedy review in blockbuster ovarian cancer market.....           Amarin?s Vascepa cuts heart risks in key trial, but placebo noise fuels controversy.....           Merck suits up for another Opdivo showdown with Keytruda liver cancer approval.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Latest news

Kingston University and Athlone Institute of Technology achieve APS accreditation


The Academy of Pharmaceutical Sciences (APS) is delighted to announce that two more institutions, Kingston University and Athlone Institute of Technology have recently achieved accreditation having gone through the accreditation process set up by the Academy towards the end of 2017.

APS is delighted that institutions see the value of our accreditation process and several others are in the process of application to us.

Achieving accreditation gives assurance to students and employers that the course meets the high standards required by the Academy and that these standards will be maintained throughout the 5-year period of accreditation.

APS believes that the accreditation process will raise the profile of pharmaceutical sciences in both academia and industry. The discipline is key in the discovery, development and manufacture of new medicines and as such is central to government initiatives to encourage the pharmaceutical industry to maintain and strengthen its strong base in the UK and Ireland.

The APS will continue to work with other stakeholders to build the science base for the ultimate benefit of patients.

APS events overview

The APS is developing an exciting and informative programme of events in 2019.

Please take a look at our programme here.

Developability for Biologicals
Inhaled Workshop
Basic Biopharmaceutics workshop 

Follow us
Upcoming Events
APS Additive Manufacturing Symposium
27 March 2019
APS Developability Workshop
17 - 18 April 2019
APS Industrial Insights 2019
25 - 26 April 2019
10th APS International PharmSci conference 2019
11 - 13 September 2019
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351, Fax: 0116 274 7365, Email:

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.

Privacy Policy:
For details on the data we collect and how we store and process your data please refer to our Privacy Policy.